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Summary Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy. Between January 1987
and March 1990, 341 consecutive previously untreated patients with multiple myeloma received chemotherapy within the prospective,
multicentre, randomized Protocol MM87. Survival was evaluated in patients aged > or < 66 years (the median age for the whole series) and
in a subgroup of patients aged < 55 years. These groups were similarfor main clinical characteristics, including results ofcytostatic treatment.
As of May 1996, 271 (79%) of the 341 patients had died, and median follow-up of the 70 (21%) living patients was 82 months. Overall,
younger patients survived longer than older ones. In fact, in patients > and < 66 years, median survival was 31 and 44 months (P< 0.00095)
and the percentage of patients surviving over 72 months was 17% and 32% (P = 0.0018) respectively; in patients < 55 years, these figures
were 57 months and 35% respectively (P= 0.02 and 0.01, with respect to patients aged .55 years). In all groups, about 50% of the patients
surviving over 72 months had stage I disease. For multiple myeloma patients treated with chemotherapy, survival is favourably affected by
relatively young age and early stage of disease.
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A typical series of patients with multiple myeloma (MM) has a
median age of about 65 years and survive a median time of about
3 years when treated with conventional chemotherapy (CT)
(Alexianan et al, 1969; Sporn et al, 1986, Osteborg et al, 1989;
Riccardi et al, 1994).
Age could influence survival, but little attention has been paid
to this topic. In some studies (Kelly et al, 1988; Cavo et al, 1989),
younger patients treated with CT tend to survive longer than older
ones, by univariate analysis. The relevance of age tends to be
lower when this parameter is included as a continuous variable
into multiple regression analysis (Grignani et al, 1995). The actual
more relevant prognostic role for relatively young age in MM is
that it is a prerequisite for administering allogeneic or autologous
bone marrow transplantation (BMT) (Fermand et al, 1993;
Jagannath et al, 1993; Bjorkstrand et al, 1994; Cunningham et al,
1994; Gharton et al, 1995; Harosseau et al, 1995, 1996; Attal et al,
1996; Bensiger et al, 1996; Marit et al, 1996; Vesole et al, 1996).
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We examined the definitive survival by age in 341 consecutive
previously untreated MM patients from the prospective, multi-
centre, randomized Protocol MM87 started in January 1987 and
closed in March 1990. The survival of patients aged less than 66
years, i.e. the median age for the whole series, is compared with
the survival of age-matched patients treated with bone marrow
transplantation (BMT) in a literature series.
MATERIALS AND METHODS
Between January 1987 and March 1990, 341 patients with
previously untreated MM entered the prospective, multicentre,
randomized Protocol MM87 (Riccardi et al, 1994).
Summary of Protocol MM87
Patients were staged (Durie and Salmon, 1975) and randomized
for both induction and maintenance therapy. A less or more
aggressive first-line induction policy was adopted for stage I
(melphalan and prednisone, MPH-P, delayed until disease progres-
sion vs MPH-P given immediately after diagnosis) and stage III
(MPH-P vs peptichemio, vincristine andprednisone, PTC-VCR-P)
patients. Patients with stage II disease were uniformly treated with
MPH-P. Response was according to slightly modified clinical
criteria adopted by the SECSG (Cohen et al, 1979), as detailed
485486 A Riccardi etal
elsewhere (Riccardi et al, 1994). Response was evaluated after six
courses ofMPH-P or four courses ofPTC-VCR-P.
Within each stage, patients who had complete or partial
response were randomized between receiving additional courses
of induction therapy until maximum reduction in the monoclonal
component (MC) (i.e. the plateau phase) was achieved (Riccardi et
al, 1994) and then stopping all cytostatics until relapse or contin-
uing therapy indefinitely until relapse, as a maintenance.
Patients who were resistant with one regimen or progressed or
relapsed during maintenance with this regimen were crossed to the
other regimen, as a second-line therapy. Hence, patients who were
originally treated with MPH-P for induction were treated with
PTC-VCR-P and patients originally treated with PTC-VCR-P
were treated with MPH-P. Patients who achieved response on
second-line treatment continued on maintenance therapy with the
same drugs until relapse.
Patients who were primarily resistant to or relapsed after a
response to first- and second-line therapies of Protocol MM87
were randomized between epirubicin and cyclophosphamide, both
combined with prednisone and a2b-IFN (Brugnatelli et al, 1996).
Data collection
Just after the first randomization, a protocol entrance form had to
be completed (specifying data that validated the diagnosis and the
stage) and a photocopy sent to the coordinating centre. Every 6
months the entrance form was updated, and cooperative group
meetings were held regularly in Pavia. Main clinical results of the
MM87 Protocol have been detailed from data analysis collected in
May 1993, when 59% of the patients had died (Riccardi et al,
1994). In May 1996, when 79% of the patients had died, a
reanalysis of survival and of causes of deaths was performed.
Medical form records or adeathcertificate-based search were used.
Table 1 Main clinical features and response to conventional chemotherapy of 341 patients whose median age was 66 (range 33-87) (stage is according to
Durie and Salmon, 1975)
Patients
> 66 years < 66 years < 55 yearsa
No. % No. % No. %
Patients 164 100 177 100 49 100
Male 85 52 83 47 22 45
Female 79 48 94 53 27 55
Serum creatinine
< 2.0 mg dl-1 146 89 152 86 44 90
> 2.0 mg dl-' 18 11 25 14 5 10
,82
< 4.0 g dl-' 28/83 34 48/105 46 13/31 42
.4.0 gg dl-1 55/83 66 57/105 54 18/31 58
ECOG/WHO PS
< 2 138 84 148 84 45 92
< 2 26 16 29 16 4 8
IgG 104 63 116 65 29 59
IgA 42 26 35 20 13 26
IgD 2 1 5 3 1 2
IgM 1 1 0 - 0 -
Light chain only 13 8 18 10 4 8
Not secreting 2 1 3 2 2 4
K 102 62 104 59 29 59
L 62 38 73 41 20 41
Stage 36 22 42 24 13 26
Stage II 46 28 47 26 14 29
Stage 1I1 82 50 88 50 22 45
Initial therapy
No therapy 15 9 25 14 6 12
MPH-P 108 66 111 63 31 63
PTC-VCR-P 41 25 41 23 12 25
Response to initial therapy
Evaluable patients 135 146 40
R (CR+PR) 62 46 61 42 17 42
NR 43 32 47 32 14 35
P 11 8 22 15 7 17
ED 19 14 16 11 2 5
aThese patients represent a subset of the whole series and are also included in the group of patients < 66 years; PS, performance status; ,2, B2 microglobulin
(available for 188 of 341 patients); MPH, melphalan; P, prednisone; PTC, peptichemio; R, response; CR, complete response; PR, partial response; NR, no
response; P, progression; ED, early death (i.e. death before response could be evaluated); MPH-P, melphalan and prednisone; PTC-VCR-P, combination
chemotherapy with the association of peptichemio, vincristine and prednisone.
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Survival by age and stage
< 66 years, 177 patients Survival was calculated from the time ofthe first randomization to
----- > 66 years, 164 patients the time of death. Survival was calculated separately for patients
P= 0.00095 aged > vs < median age for the whole series, i.e. for patients aged
> vs < 66 years. Additionally, survival was also calculated for
patients aged < 55 years, the age that is considered to be the upper
limit for allogeneic bone marrow transplantation (Ballester et al,
1993; Gharton et al, 1995).
In all groups, survival was also calculated by stage of disease
and response to cytostatic treatment.
20 40 60 80 100 120 Statistical analysis
Months from diagnosis
Figure 1 Survival by age groups of patients with MM treated with
conventional chemotherapy
Table 2 Clinical features of patients who survived > 72 months whose
median age was 63 (range 38-79) years (abbreviations as in Table 1)
Patients
> 66 years < 66 years
No. % No. %
Patients 28/164 17 56/177 32
Male 15 53 23 41
Female 13 47 33 59
Serum creatinine
<2.0 mg dl-' 27 97 52 93
2 2.0 mg dl-' 1 3 4 7
12
< 4.0jg dl-' 15/19 79 13/29 45
2 4.0 igg dl-' 4/19 21 16/29 55
ECOG/WHO
< 2 26 93 50 89
>2 2 7 6 11
IgG 19 68 42 75
IgA 8 29 11 20
IgD 0 0 1 1.5
IgM 0 0 0 0
Light chain only 0 0 0 0
Not secreting 1 3 2 3.5
K 21 75 33 59
L 7 25 23 41
Stage 14 50 26 46
Stage II 7 25 15 27
Stage 1I1 7 25 15 27
Initial therapy
No therapy 4 14 17 30
MPH-P 20 72 31 56
PTC-VCR-P 4 14 8 14
First-line therapy
Evaluable patients 23/28 82 40/56 71
R (CR + PR) 14 61 20 50
NR 9 39 16 40
P 0 0 4 10
Survival curves were obtained using the method of Kaplan and
Meier (1958). Patients were considered to be alive if their last
evaluation was within 6 months, and death was not documented.
All deaths were considered as events regardless of their cause.
Differences in overall survival between groups were analysed
using the log-rank test, taking censored data into account.
RESULTS
Theresults ofthis study are reported inTables 1-4 and Figures 1-4.
At the time ofthis reanalysis (May 1996), 271 (79%) ofthe 341
patients who entered the Protocol MM87 had died and the median
follow-up ofthe 70 (21%) living patients was 82 months.
Patients characteristics
The series ofpatients > and < 66 years and less than 55 years were
similar for main clinical characteristics (Table 1). There was no
indolent and / or smouldering MM.
Median survival of patients aged > or < 66 years
Ten years after starting the MM87 protocol, prognosis was worse
forpatients > 66 years than forpatients < 66 years. In fact, patients
> and < 66 years survived a median of 31 and 44 months respec-
tively (P = 0.00095) (Figure 1), with first-response duration not
significantly different in the two groups [25.1 (1-57) months and
22.8 (1-60) months].
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Figure 2 Survival by age groups of patients with stage MM treated with
conventional chemotherapy
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Figure 3 Survival by age groups of patients with stage 11 + III MM treated
with conventional chemotherapy
The intensity of treatment tended to be greater for the younger
patients. Both first- and second-line treatment were completed in
similar numbers ofpatients < or 66 years, butpatients < 66 years
were more often able to be treated with third- and fourth-line
chemotherapies. In fact, first- and second-line treatments were
completed in 82.3% and 82.4% of 135 and 146 patients and in
78.2% and 79.2% of 87 and 96 patients > and < 66 years respec-
tively. On the contrary, third-line chemotherapy could be delivered
to 26 and 57 patients > and < 66 years respectively.
Overall, 84 out of 341 (24.6%) initially recruited patients
survived 6 years or longer, and 19 out of 84 (23%) of them had
died at the time ofthis analysis (12%, 27% and 36% of stage I, II
and III respectively).
The main clinical characteristics of these patients with longer
survival are reported in Table 2. Median age was 63 years. Between
the whole series (Table 1) and the 'long-survivors' series (Table 2),
there were no significant differences in the clinical features (serum
creatinine, P2-microglobulin, ECOG/WHO perfonnance status,
type of M component, stage) and initial cytostatic treatment and
response to it. The only significant difference between the whole
and long-survivors series was that48% (46-50%) oflong survivors
had stage I disease, while this stage accounted for only 23%
(22-26%) ofthe starting population.
Months from diagnosis
Figure 4 Survival of MM patients aged less than 55 years treated with
conventional chemotherapy
Survivors over 6 years were 17% and 32% among patients
> and < 66 years respectively (P = 0.0018) (Figure 1).
For stage I patients aged > 66 and < 66 years, median survival
was 50 months and not reached at 100 months respectively. The 6-
year survival was 39% and 65% respectively (P = 0.0089) (Figure
2). For stage II and III patients aged > or < 66 years, median
survival was 27 and 36 months respectively (P = 0.017). The 6-
year survival was 11% and 22% respectively (P = 0.14) (Figure 3).
For complete or partial responders with stage II and III disease
aged > or < 66 years (54 and 58 patients respectively), median
survival was 38 and 50 months respectively (P = 0.017). The 6-
year survival was 18% and 26% respectively (P = 0.3) (Table 3).
Median survival of patients aged less than 55 years
The subgroup of 49 patients < 55 years survived a median of 57
months (P = 0.022 with respect to survival ofpatients 55 years)
(Figure 4) and 35% ofthem survived more than 6 years (P = 0.012
with respect to survival ofpatients 2 55 years).
Median survival was not reached at 100 months for 13 stage I
patients; it was 73 months for 14 stage II patients and 38 months
for 22 stage III patients. The 6-year survival was 54% (7 of 13
patients) for stage I, 50% (7 of 14 patients) for stage II and 14%
(3 of22 patients) for stage III patients.
Table 3 Cumulative survival data for patients with multiple myeloma in the present series
Age group Patients (no.) Median survival Percentage of patients Percentage of patients
(months) alive at 4 years alive at 6 years
> 66 years 164 31 30 17
Stagel 36 50 56 39
Stage 11+ III 128 27 23 11
Responsive stage 11 + liI 54 38 37 18
<66Years 177 44 46 32
Stage I 42 > 100 79 65
Stage II +ll 135 36 36 22
Responsive stage 11 + III 58 50 50 26
< 55 yearsa 49 57 53 35
Stage I 13 > 100 69 54
Stage II 14 73 71 50
Stage 1il 22 38 32 14
aThese patients represent a subset of the whole series and are also included in the group of patients < 66 years.
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Table 4 Causes of death of patients with multiple myeloma in the present series (the distribution of causes of death is not significantly different among the
different groups)
> 66 years < 66 years Overall < 55 yearsa
Patients who died (no.) 139 132 271 36
Patients whose cause of death is known (no.) 92 83 175 21
Causes related to MM [no. (%)] 63 (68.5) 67 (80.7) 130 (74.3) 15 (71.4)
Infections (no.) 24 25 49 3
Renal insufficiency (no.) 17 18 35 3
Hypercalcaemia (no.) 7 17 24 6
Hyperviscosity (no.) 4 0 4 0
Other (no.) 11 7 18 3
Causes poorly or not related to MM [no. (%)] 29 (31.5) 16 (19.3) 45 (25.7) 6 (28.6)
Stroke (no.) 12 3 15 1
Myocardial infarction (no.) 2 8 10 2
Heart failure (no.) 5 2 7 1
Solid tumours (no.) 8 0 8 0
Acute leukaemia (no.) 1 1 2 0
Peritonitis (no.) 1 0 1 0
After BMT (no.) 0 2 2 2
aThese patients represent a subset of the whole series and are also included in the group of patients < 66 years.
Table 3 summarizes the survival of patients with MM treated
with CT within the MM87 Protocol, according to age, stage and
response to chemotherapy.
Causes of death
Causes ofdeath couldbe ascertained for 175 of271 patients (Table
4). There were no differences in the percentage distribution of
causes of death that were related or unrelated to MM among the
three groups aged > 66 years, < 66 years and < 55 years.
DISCUSSION
The reanalysis of Protocol MM87 indicates that relatively young
age is a favourable prognostic factor in MM treated with CT, inde-
pendent ofthe type ofinitial cytostatic treatment (MPH-P or PTC-
VCR-P). In fact, patients aged more than 66 years (median age of
this series) andpatients aged 66 years orless survived for amedian
time of 31 and 44 months respecti-vely; among the two groups,
patients who survived over 72 months were 17% and 32% respec-
tively. Prognosis was even better in the subgroup ofpatients aged
less than 55 years, who survived a median time of 57 months and
the 35% of whom survived over 72 months. A possible cause for
better survival of younger patients could be that these patients are
better able to tolerate subsequent treatments (as third- and fourth-
line chemotherapies), possibly because of a better-maintained
performance status and areduced frequency ofintercurrent illness.
The comparison of survival of patients aged < 66 years treated
with CT with that of age-matched groups of patients treated with
bone marrow transplantation (BMT) is feasible to a limiteddegree.
A major cause for this limitation is that the follow-up of most
BMT series is relatively short (4 years or, more often, 3 years), so
that putative end results for evaluable patients are actually
expressed as 'probability' or 'projection' ofbeing long-term alive
or disease free. In contrast, data from our series are substantially
conclusive, as patients were recruited between 1987 and 1990 and
survival is updated in 1996. Another well-known difficulty in
Table 5 Survival of relatively young patients with stage I-Ill MM treated
with bone marrow transplantation (BMT) or with conventional chemotherapy
(data from literature series and present series)
Autologous BMT' Conventional
chemotherapyb
No. of patients 976 177
Upper age (Years)
Median 66 66
Range 64-69
Median age (years) 49-52 58
BMT-related mortality (%) (range) 6 (2-25) 0
Four-year survival (%) (range) 40 (32-63) 46
Median survival (months) 28-41 44
aJagannath et al (1993); Bjorkstrand et al (1994); Cunningham et al (1994);
Bensiger et al (1996); Vesole et al (1996). bPresent series.
comparing CT and BMT series is that early BMT-related mortality
accounts for a variable percentage (from 2% to 25%) of early
deaths, so that median survival tends to be lowered in transplanted
MM. Finally, the minor drawbacks are the partly different compo-
sition of the series and the fact that reports from BMT procedures
exclude from evaluation a different number ofpatients, because of
different reasons.
With these limitations in mind, Tables 5 and 6 attempt this
comparison. The tables are compiled using median and 4-year
survival, as the commonest data can be found in most BMT series
(Fermand et al, 1993; Jagannath et al, 1993; Bjorkstrand et al,
1994; Cunningham et al, 1994; Harosseau et al, 1995; Attal et al,
1996; Bensiger et al, 1996; Marit et al, 1996; Vesole et al, 1996)
and are useful for comparison with our series (Table 3).
Additionally, for literature series, data on 4-year survival given by
the authors (as a % of single series) have also been cumulated by
calculating the actual percentage ofpatients of all series surviving
4 years.
Evaluating all MM stages (I toIII) aged < 66 years (Table 5), the
4-year survival is 46% in our series and 40% (32-63%) in five
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Table 6 Survival of relatively young patients with stage 11-l1l MM treated with bone marrow transplantation (BMT) or with conventional chemotherapy (data
from literature series and present series)
Autologous Conventional Conventional
BMT' chemotherapy chemotherapy
(all patlents)b (responsive patients)
No. of patients 369 234 135
Upper age (years)
Median 63 65 64.5
Range 58-66 64-66 64-65
Median age (years) 44-57 56-58 56-58
BMT-related mortality (%) (range) 5 (3-11) 0 0
Four-year survival (range) 58 (55-65) 36(35-37) 53 (50-56)
Median survival (months) 46-59 36-37 50-60
aFermand et al (1993); Harousseau et al (1995); Attal et al (1996); Marit et al (1996). bPresent series; Attal et al (1996). cPresent series; Blade et al (1996).
autologous BMT series with lower median age (Jagannath et al,
1993; Bjorkstrand et al, 1994; Cunningham et al, 1994; Bensiger
et al, 1996; Vesole et al, 1996). Median survival was 44 months
in our series and 28-41 months in autologous BMT series
(Jagannath et al, 1993; Bjorkstrand et al, 1994; Besinger et al,
1996; Vesole et al, 1996).
In the only published series in which patients aged less than 55
years were treated with allogeneic BMT (Gahrton et al, 1995),
median survival was 17 months and 4-year survival was 34%. The
corresponding figures for our < 55 years patients are 57 months
and 46% (Figure 4).
Some of the autologous BMT series in the literature (Fermand
et al, 1993; Harousseau et al, 1995; Attal et al, 1996; Marit et al,
1996) exclude stage I patients from transplantation procedures
because ofthe intrinsic good prognosis ofthese patients. Actually,
in our series also, early disease was a contributing factor for long
survival. In fact, the 46-50% of patients surviving over 6 years
were stage I MM, compared with the 22-26% with stage I disease
included in the whole series. With these exclusions, stage II and III
disease accounts for 71-89% (the weighted mean value is 75%) of
patients in the autologous BMT series and for 65% of patients in
our series.
The 4-year survival for transplanted stage II and III is 58%
(55-65%) (Fermand et al, 1993; Harousseau et al, 1995; Attal et
al, 1996; Marit et al, 1996) and median survival ranges from 46 to
59 months (Table 6). Actually, the 58% 4-year survival calculated
in the autologous BMT series is optimistic, as the 61% and 65% 4-
year survival figures projected in two (Attal etal, 1996; Marit etal,
1996) ofthese series need to be confirmed with a longerfollow-up
than the actual follow-up of41 and 27 months respectively (Atkis,
1996; Oivanen and Palva, 1996).
With CT, the 4-year survival for all stage II and Ill patients was
lower, i.e. 36% (35-37%) in our and in another literature series
(Attal et al, 1996) and median survival was 36 and 37 months.
However, results are improved when CT-responding patients are
considered, who are often the true candidates for transplantation
(Blade et al, 1996). In fact, the 4-year survival forresponsive stage
II-III patients was 53% (50-56%) (Blade et al, 1996; present
series) and median survival was 50 months and about 60 months
respectively. However, the fact that the age of conventionally
treated patients is higher than the age oftransplanted patients must
still be accounted for (Table 6).
Summarizing these data, there is no apparent advantage in
treating all relatively young MM patients with BMT rather than
with CT (Table 5), because 4-year survival is similar and median
survival is shorter with BMT than with CT. For stage LI-III MM
(Table 6), autologous BMT could offer some advantage over CT,
because median survival is similar with the two procedures and 4-
year survival is superior with BMT. However, the BMT advantage
actually disappears when comparing the prognosis of
chemotherapy-responsive patients (who are theusual candidates to
BMT) with that oftransplanted stage II-III patients.
Two obvious points need to be emphasized. First, a longer
follow-up ofBMT series is needed for comparing definitive BMT
with definitive CT survival data, such as thoseoriginating fromthe
MM87 Protocol. Second, prospective randomized studies, with
adequate follow-up, could evaluate the relative advantage of
treating relatively young MM patients with CT or with BMT.
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